Overactive bladder(OAB)
Conditions
Interventions
The administration of Mirabegron 50mg
The administration of fesoterodine 4mg
Sponsors
Nagasaki University Hospital Department of urology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)More than 3 points in total OABSS and more than 2 points in OABSS-Q3(urinary urgency episodes more than 1 per week) 2)Untreated Patients of overactive bladder. 3)Patients more than 20 years old. 4)Regardless of gender. 5)Ability and willingness to provide written informed consent and comply with the requirements of the study protocol
Exclusion criteria
Exclusion criteria: Patients were excluded if they received treatment with anticholinergic agents,beta3-adrenoceptor agonist,BOTOX injection,propafenone hydrochloride or flecainide acetate; if they had hypersensitivity to mirabegron,fesoterodine or tolterodine; if they had renal dysfunction,hepatic dysfunction,severe cardiac disease,urinary retention,closed-angle glaucoma,ileus,atony or myasthenia gravis; if they are not able to answer questionnaires and they need proxies; if they are pregnant or want to have a baby in the future; and if they pacitipated other clinical research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of 3 points or more in total OABSS(OAB symptom scores) after 12 weeks' treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Less than 1 point in OABSS-Q3 or less than 2 ponits in total OABSS score after 12 weeks' treatment | — |
Countries
Japan
Contacts
Public ContactHidenori Ito
Nagasaki University Hospital Department of urology
Outcome results
None listed